New Alzheimer's drugs, lecanemab and donanemab, are the first FDA-approved treatments shown to slow the disease's progression rather than only ease its symptoms. Families weighing memory care decisions are asking what these medications can realistically do, who qualifies for them, and what they cost. These drugs are lab-made antibodies given by infusion that clear a sticky protein called amyloid from the brain and, in clinical trials, slowed cognitive decline by roughly a quarter to a third in people with early-stage Alzheimer's disease.
For most families, that is a meaningful but modest result, not a cure. Understanding what the drugs do, who they help, and how they fit alongside other care decisions matters more than the headlines.
What Are the New Alzheimer's Drugs Approved So Far?
Two anti-amyloid drugs are now approved and available: lecanemab (brand name Leqembi) and donanemab (brand name Kisunla). Both target amyloid plaques, a hallmark of Alzheimer's disease found in the brain. They are given only to people in the earliest stages of the disease, not to those with moderate or advanced dementia.
Both drugs received traditional FDA approval after large clinical trials measured how quickly people declined on standard cognitive and daily-function scales. Neither drug restores memory that has already been lost. Both are intended to slow further decline while a person is still in the mild cognitive impairment or mild dementia stage.
| Drug | Brand Name | Typical Dosing | Key Consideration |
|---|---|---|---|
| Lecanemab | Leqembi | Infusion every two weeks | Ongoing infusions with no planned stop date |
| Donanemab | Kisunla | Infusion every four weeks | May be stopped once amyloid clears from scans |
How Do These Drugs Actually Work?
Lecanemab and donanemab work by binding to amyloid protein in the brain and helping the body clear it away. Removing amyloid does not reverse existing damage, but trial data showed it can slow the pace of further cognitive and functional decline over roughly 18 months.
The effect size in trials was consistent but not dramatic. Researchers described it as adding several months of preserved function compared with no treatment, which matters most when caught early. The National Institute on Aging has detailed how these therapies fit into the current treatment picture for Alzheimer's disease.
Talk to a Local Advisor
Free help comparing communities and current pricing in your area. No cost, no pressure.
Who Actually Qualifies for Treatment?
A person generally qualifies only if imaging or a spinal fluid test confirms amyloid buildup and their symptoms fall in the mild cognitive impairment or early dementia range. People with moderate or severe Alzheimer's are not candidates because the trials did not test the drugs at that stage.
Doctors also typically recommend genetic testing for the APOE4 gene before starting treatment, since carriers face a higher risk of brain swelling or bleeding from the medication. A full diagnostic workup, including brain scans, blood draws, and sometimes a lumbar puncture, usually takes several weeks before infusions can begin.
Common qualifying steps include:
- Diagnosis confirmation: A neurologist confirms Alzheimer's disease through cognitive testing and brain imaging or biomarker tests.
- Amyloid confirmation: A PET scan or spinal fluid test shows amyloid plaques are actually present.
- Genetic screening: Blood testing for the APOE4 gene helps estimate the risk of side effects.
- Baseline MRI: A brain scan establishes a starting point before any infusions begin.
What Are the Risks Families Should Know About?
The main safety concern is a condition called ARIA, short for amyloid-related imaging abnormalities, which involves brain swelling or small areas of bleeding. Most cases are mild and show up only on scheduled MRI scans, but some people develop headaches, confusion, or vision changes, and rare severe cases have been fatal.
Because of this risk, anyone on these drugs needs periodic MRI monitoring throughout treatment, especially during the first several months. People taking blood thinners face added risk and need closer supervision. Families should ask the prescribing neurologist directly how often scans will happen and what symptoms warrant an emergency call.
Does Medicare Cover These Drugs?
Medicare Part B covers lecanemab and donanemab for people who meet the FDA-approved criteria and whose doctor participates in a qualifying registry that tracks outcomes. Coverage also extends to the PET scans, blood tests, and follow-up MRIs required around treatment, though standard Part B cost-sharing still applies.
Details on what is covered and under what conditions are outlined on Medicare.gov. Medicare Advantage plans must offer at least the same coverage, though prior authorization and in-network requirements vary by plan.
What Do These Drugs Cost Out of Pocket?
Even with Medicare coverage, families should expect meaningful out-of-pocket costs from coinsurance, since Part B typically covers 80 percent of the drug and leaves the remaining 20 percent to the patient unless a supplemental policy fills the gap. The list price for a year of treatment runs in the tens of thousands of dollars before insurance.
Add in the diagnostic workup, repeat MRIs, and specialist visits, and the true annual cost to a family can be substantial even after Medicare pays its share. A Medicare Supplement (Medigap) policy or Medicaid, for those who qualify, can significantly reduce what a family pays directly.
What Should a Family Expect Day to Day?
Treatment means a recurring commitment: infusion appointments every two to four weeks, periodic MRI scans, and follow-up visits with a neurologist to track progress and side effects. Someone will usually need to arrange transportation to and from an infusion center, since appointments can take an hour or more and some people feel tired afterward.
This logistical load is worth naming honestly. For a family already juggling work, other caregiving duties, and a parent's changing needs, the appointment schedule alone can be a significant addition, separate from how the person responds to the medication itself.
Some infusion centers offer flexible scheduling or home-infusion options, but availability depends heavily on location and the specific clinic. Rural families in particular may need to weigh long drive times against the potential benefit, which is a conversation worth having with the prescribing doctor before committing to a treatment schedule.
Prefer to talk it through? A local advisor can answer your questions and compare current pricing, free.
(385) 200-2175Do These Drugs Change How Families Should Plan for Care?
A modest slowing of decline does not remove the need for a care plan; it can shift the timeline. Families may have more months where an aging adult manages daily routines with less help, but the underlying disease is still progressing and care needs will still increase over time.
It still makes sense to research options early, including memory care and broader dementia care planning, rather than waiting until a crisis forces a fast decision. Understanding how the disease typically unfolds stage by stage also helps families set realistic expectations for what treatment can and cannot change.
A slightly longer plateau in the early stage can also be a practical window. Families sometimes use that extra time to tour communities, put legal and financial paperwork in order, or simply have conversations about future care preferences while an older adult can still take part in the decisions.
When to Talk to a Local Advisor
Deciding whether to pursue one of these treatments, and how it fits alongside a broader care plan, is a conversation worth having with both a neurologist and someone who knows the local care landscape. A local senior living advisor can help a family understand how memory care and other dementia care options line up with a parent's current stage and how a change in trajectory might affect timing.
For background on how Alzheimer's disease typically progresses and what to watch for at each stage, the National Institute on Aging's treatment overview and Medicare's coverage page are good starting points before that conversation.
This article is informational only and is not medical, legal, or financial advice. Confirm details with the relevant professional or agency before acting.
